Suspended
A Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
What is being tested
Data Collection
Who is being recruted
Airway Obstruction+7
+ Lung Diseases
+ Lung Neoplasms
Over 18 Years
+21 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Study Start: October 2012
Summary
Principal SponsorNanospectra Biosciences, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 1, 2012
Actual date on which the first participant was enrolled.This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escalating dose of laser radiation delivered by optical fiber via bronchoscopy.
Official TitleA Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
Principal SponsorNanospectra Biosciences, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
1 patient to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Airway ObstructionLung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteRespiration DisordersRespiratory InsufficiencyRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic Neoplasms
Criteria
12 inclusion criteria required to participate
Subjects must have documented histological or cytological evidence of tumor(s) of the lung.
Subjects must have one or more primary or metastatic tumors of the lung which have at least 10 mm in long axis as evaluated by spiral CT scan evaluation performed within last 30 days.
Target lesions should be accessible to examination (examination by fiberoptic bronchoscopy is permitted) and to biopsy.
Each index lesion should be large enough to provide at least 6 mg of tumor tissue by biopsy for assessment by neutron activation analysis.
Show More Criteria
9 exclusion criteria prevent from participating
Subjects with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold).
Patients who are pregnant and/or lactating.
Patients who have undergone splenectomy.
Subjects who are receiving concurrent investigational therapy or who have received investigational therapy within the 30 days prior to AuroShell infusion (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication).
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
Cancer Treatment Centers of America Eastern Regional Medical Center
Philadelphia, United StatesOpen Cancer Treatment Centers of America Eastern Regional Medical Center in Google MapsSuspendedOne Study Center